GEN Exclusives

More »

GEN News Highlights

More »
Dec 13, 2011

Pharmalink Licenses Archimedes' Targit Enteric Delivery Technology

  • Pharmalink negotiated an exclusive global license to formulate its lead corticosteroid candidate Nefecon® using Archimedes Pharma’s TARGIT® gastrointestinal drug delivery technology. Nefecon is in mid-late stage trials for the treatment of IgA nephropathy, and to date has been codeveloped with Archimedes using the latter’s enteric delivery platform. 

    The firms initiated their codevelopment program for Nefecon in 2004, but the new licensing agreement means that Pharmalink will assume full control and responsibility for further development of the drug. Archimedes will receive an up-front payment, and royalties on future sales of Nefecon. The firm also retains all rights to the TARGIT platform for non-Nefecon applications. An open-label Phase II study with Nefecon has been successfully completed in Sweden, and Pharmalink says pivotal studies are being planned.

    “Our collaboration with Archimedes delivered very strong progress, and having secured an exclusive license to TARGIT we look forward to continuing to drive the development of Nefecon,” comments Johan Haggblad, Pharmalink MD. 

Add a comment

  • You must be signed in to perform this action.
    Click here to Login or Register for free.
    You will be taken back to your selected item after Login/Registration.

Related content


GEN Jobs powered by connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
More »

Be sure to take the GEN Poll

Easing Restrictions for Terminal Patients

Should the Federal Government Pass a “Right to Try” Bill Allowing Terminally Ill Patients Access to Experimental Medicines?

More »